Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Dose adjustment of follicle-stimulating hormone (FSH) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: a systematic review covering 10 years (2007-2017).
Fatemi | Reprod Biol Endocrinol. 2021;19(1):68.
US Human Factors Engineering Evaluation of an Updated Follitropin Alfa Pen Injector (GONAL-f® RFF Redi-ject®) and Instructions for Use.
Mahony | Expert Opin Drug Deliv. 2018;15(1):5-15.
Recombinant human follicle-stimulating hormone alfa dose adjustment in US clinical practice: an observational, retrospective analysis of a real-world electronic medical records database.
Mahony | Front Endocrinol (Lausanne). 2021;12:742089.
Human factors engineering and design validation for the redesigned follitropin alfa pen injection device.
Mahony | Expert Opin Drug Deliv. 2015;12(5):715-725.
Fine-tuning the dose of recombinant human follicle-stimulating hormone alfa to individualize treatment in ovulation induction and ovarian stimulation cycles: a real-world database analysis
Martini | Front Endocrinol (Lausanne). 2023;14:1195632.
The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review.
Velthuis | Adv Ther. 2020;37(12):4831-4847.
This site is intended for US healthcare professionals only.
DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.
US-MULNP-00023 09/24
By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.
Help us direct you to the right information by selecting one of the following options: